Prof Iain Macdougall
Consultant Nephrologist, Lead for Renal Research and Development
- Year Qualified
- 1983
- Qualifications
- BSc (Hons), MB, ChB, MD, FRCP
- Specialty
- Renal
Special Interests
- Anaemia of kidney disease
Biography
Prof Macdougall was appointed as a Consultant Nephrologist in January 1996, and received his academic promotion to Professor of Clinical Nephrology through King’s College London in March 2011.
His sub-specialty interest is the anaemia associated with chronic kidney disease, for which he is internationally renowned. He is also the R&D Lead for the Renal Department at King’s, as well as the South London Renal CLRN lead for the NIHR network.
With his research team, he has led several pivotal multicentre clinical trials, which have shaped the management of renal anaemia worldwide. He was selected to be on an international Work Group (KDIGO) to create the latest clinical practice guideline for the management of anaemia in chronic kidney disease, which was published in August 2012.
Related services
Research
-
Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW, Silver S, Murday AS, Armitage JO, Goldsmith D (2012) ‘A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR)‘, Seminars in thrombosis and hemostasis, 38,(8):783-96
-
Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU (2009) ‘A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia‘, The New England journal of medicine, 361,(19):1848-55
-
Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators (2007) ‘The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study‘, Clinical nephrology, 67,(5):306-17
-
Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B (2006) ‘Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease‘, Clinical journal of the American Society of Nephrology : CJASN, 1,(6):1211-5
-
Macdougall IC (2005) ‘CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia‘, Current hematology reports, 4,(6):436-40
-
Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC (2004) ‘Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure‘, Journal of the American Society of Nephrology : JASN, 15,(7):1877-82
-
Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC (2004) ‘Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study‘, Lancet, 363,(9423):1768-71
-
Macdougall IC (2004) ‘Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another‘, Current medical research and opinion, 20,(1):83-6
-
Winkler AS, Peters TJ, Marsden JT, Deacon AC, Chandler G, Macdougall IC (2003) ‘Erythropoietin treatment in the neuropsychiatric porphyrias‘, Clinica chimica acta; international journal of clinical chemistry, 338,(1-2):61-6
-
Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC (2003) ‘Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy‘, Journal of the American Society of Nephrology : JASN, 14,(7):1776-84
-
Cooper AC, Breen CP, Vyas B, Ochola J, Kemeny DM, Macdougall IC (2003) ‘Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production‘, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 18,(1):133-40
-
Macdougall IC, Cooper AC (2002) ‘Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines‘, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 17 Suppl 11,():39-43
-
Bosman DR, Osborne CA, Marsden JT, Macdougall IC, Gardner WN, Watkins PJ (2002) ‘Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure‘, Diabetic medicine : a journal of the British Diabetic Association, 19,(1):65-9
-
Winkler AS, Marsden J, Deacon A, Wilson S, Chandler G, Macdougall IC, Peters TJ (2002) ‘Serum erythropoietin levels may be inappropriately low in the acute neuropsychiatric porphyrias‘, Clinica chimica acta; international journal of clinical chemistry, 317,(1-2):93-100
-
Macdougall IC (2001) ‘Ace inhibitors and erythropoietin responsiveness‘, American journal of kidney diseases : the official journal of the National Kidney Foundation, 38,(3):649-51
-
Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ (2001) ‘Anemia with erythropoietin deficiency occurs early in diabetic nephropathy‘, Diabetes care, 24,(3):495-9
-
Macdougall IC (1999) ‘Optimizing erythropoietin therapy‘, Current opinion in hematology, 6,(3):121-6
-
Breen CP, Macdougall IC (1998) ‘Improvement of erythropoietin-resistant anaemia after renal transplantation in patients with homozygous sickle-cell disease‘, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 13,(11):2949-52
-
Macdougall IC (1998) ‘Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin‘, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 13 Suppl 2,():23-7
-
Drüeke TB, Bárány P, Cazzola M, Eschbach JW, Grützmacher P, Kaltwasser JP, Macdougall IC, Pippard MJ, Shaldon S, van Wyck D (1997) ‘Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients‘, Clinical nephrology, 48,(1):1-8
-
Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE (1996) ‘A randomized controlled study of iron supplementation in patients treated with erythropoietin‘, Kidney international, 50,(5):1694-9
-
Macdougall IC (1995) ‘Poor response to erythropoietin‘, BMJ (Clinical research ed.), 310,(6992):1424-5
-
Macdougall IC (1995) ‘Poor response to erythropoietin: practical guidelines on investigation and management‘, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 10,(5):607-14
-
Macdougall IC (1994) ‘Monitoring of iron status and iron supplementation in patients treated with erythropoietin‘, Current opinion in nephrology and hypertension, 3,(6):620-5
-
Lewis NP, Macdougall IC, Willis N, Coles GA, Williams JD, Henderson AH (1993) ‘Effects of the correction of renal anaemia by erythropoietin on physiological changes during exercise‘, European journal of clinical investigation, 23,(7):423-7
-
Thuraisingham RC, Roger SD, Macdougall IC, Cavill I, Stephens AD, Baker LR, Raine AE (1993) ‘Improvement in anaemia following renal transplantation but not after erythropoietin therapy in a patient with sickle-cell disease‘, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 8,(4):371-2
-
Lipkin GW, Macdougall IC, Raine AE (1993) ‘Prolonged elevation of plasma atrial natriuretic factor does not increase erythropoietin levels in patients with chronic renal failure‘, Nephron, 65,(4):640-1
-
Macdougall IC (1992) ‘Treatment of renal anemia with recombinant human erythropoietin‘, Current opinion in nephrology and hypertension, 1,(2):210-9
-
Coles GA, Liberek T, Davies ME, Robinson M, Jones J, Thomas G, Davies M, MacDougall IC, Williams JD (1992) ‘Estimation of erythropoietin secretion rate in normal and uremic subjects‘, The American journal of physiology, 263,(5 Pt 2):F939-44
-
Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD (1992) ‘Detection of functional iron deficiency during erythropoietin treatment: a new approach‘, BMJ (Clinical research ed.), 304,(6821):225-6
-
Roger SD, Macdougall IC, Thuraisingham RC, Raine AE (1991) ‘Erythropoietin in anemia of renal failure in sickle cell disease‘, The New England journal of medicine, 325,(16):1175-6
-
Roger SD, Macdougall IC, Raine AE (1991) ‘Phlebotomy for erythropoietin-associated malignant hypertension‘, Lancet, 337,(8757):1606
-
Macdougall IC, Davies ME, Hutton RD, Coles GA, Williams JD (1991) ‘Rheological studies during treatment of renal anaemia with recombinant human erythropoietin‘, British journal of haematology, 77,(4):550-8
-
Macdougall IC, Roberts DE, Coles GA, Williams JD (1991) ‘Clinical pharmacokinetics of epoetin (recombinant human erythropoietin)‘, Clinical pharmacokinetics, 20,(2):99-113
-
Macdougall IC, Hutton RD, Coles GA, Williams JD (1991) ‘The use of erythropoietin in renal failure‘, Postgraduate medical journal, 67,(783):9-15
-
Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, Williams JD (1991) ‘Subcutaneous erythropoietin therapy: comparison of three different sites of injection‘, Contributions to nephrology, 88,():152-6; discussion 157-8
-
Macdougall IC, Davies ME, Hallett I, Cochlin DL, Hutton RD, Coles GA, Williams JD (1991) ‘Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients‘, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 6,(11):862-7
-
Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD (1990) ‘Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm‘, BMJ (Clinical research ed.), 300,(6725):655-9
-
Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD (1990) ‘Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin‘, Lancet, 335,(8688):489-93
-
Macdougall IC, Davies ME, Hutton RD, Cavill I, Lewis NP, Coles GA, Williams JD (1990) ‘The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin‘, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association, 5,(11):950-5
-
Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD (1989) ‘Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously‘, BMJ (Clinical research ed.), 299,(6692):157-8
-
MacDougall IC, Roberts DE, Coles GA, Williams JD (1989) ‘Intraperitoneal erythropoietin‘, Lancet, 1,(8651):1389
-
Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD (1989) ‘Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis‘, Lancet, 1,(8635):425-7
-
Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD (1989) ‘Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment‘, Contributions to nephrology, 76,():112-20; discussion 120-1
-
Macdougall IC, Cavill I, Davies ME, Hutton RD, Coles GA, Williams JD (1989) ‘Subcutaneous recombinant erythropoietin in the treatment of renal anaemia in CAPD patients‘, Contributions to nephrology, 76,():219-26